Crimson Publishers Publish With Us Reprints e-Books Video articles

Abstract

Modern Approaches in Drug Designing

PARP Inhibitors: A Breakthrough in Cancer Chemotherapy

  • Open or Close Mohd Imran Ansari, Chad Johnson and Andrew Coop*

    Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, USA

    *Corresponding author: Andrew Coop, Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, USA, Tel: +1410-706-2029; Email: acoop@rx.umaryland.edu

Submission: April 04, 2018; Published: May 15, 2018

ISSN : 2576-9170
Volume2 Issue1

Abstract

Among the 17 members of Poly (ADP-ribose) polymerase enzyme family, PARP-1 is a very crucial DNA repair enzyme and the level of PARP-1 is found elevated in several cancers such as ovarian, triple negative breast cancer. Inhibitors of PARP -1 is a new feature of anticancer drug development. In this mini, we covered the mode of action, recent development and approval of PARP-1 inhibitors. We also provide an insight on designing strategy of novel PARP-1 inhibitors and future direction.

Keywords: PARP inhibitors; Poly ADP ribose polymerase (PARP) family; Single strand break repair; Breast Cancer; Ovarian Cancer; DNA lipase

Abbreviations: PARP: Poly ADP Ribose Polymerase; SSBR: Single Strand Break Repair; CAT: C-Terminal Catalytic Domain; PARG: Poly(ADP-ribose) Glycohydrolase; SAR: Structure-Activity Relationship

Get access to the full text of this article